ClinicalTrials.gg
CompletedNCT01905670SELECT-LVUpdated Jul 9, 2020

Safety and Performance of Electrodes Implanted in the Left Ventricle

An interventional study of WiCS-LV system in Heart Failure, Ventricular Dysfunction and Cardiomyopathies, sponsored by EBR Systems, Inc.. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-07-09.

Sponsored by EBR Systems, Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
39
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 166 studies in Heart Failure with a site in Czechia — 36 open to participants now, 45 under way, 14 of them phase 3. Heart Failure · Czechia.

Enrollment
121st of 136
39 · median 456
Started
2013
with 9 others
No phase
34 of 166
9 open now
Registered
51st of 166
by date

Among the 166 studies in Heart Failure with a site in Czechia, this one is the 121st largest by enrollment of the 136 interventional ones that give a count, is one of 10 that started in 2013, is one of 34 with no phase, and was the 51st registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

36 of the 166 studies in Heart Failure with a site in Czechia are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 166 studies in Heart Failure with a site in Czechia, or all of them as a file.
02

Study summary

The study is intended to demonstrate the safe implant of small receiver-electrodes into the endocardial surface of the left ventricle and to demonstrate its utility in providing cardiac resynchronization therapy in heart failure patients.

Read the detailed description

Eligible patients will undergo an acoustic window assessment using transthoracic echocardiography. Patients with adequate acoustic windows will undergo implantation of the WiCS-LV system.

Patients will undergo evaluations pre-hospital discharge, and at one month, 3 months, and 6 months post implantation. Extended follow-up will be obtained via a registry at 1, 2, 3, 4, and 5 years post implantation.

03

Conditions studied

  • Heart Failure
  • Ventricular Dysfunction
  • Cardiomyopathies
  • Heart Diseases
  • Cardiovascular Diseases

Keywords

  • Cardiac Resynchronization Therapy
  • cardiac pacing
  • electrical stimulation
  • bi-ventricular pacing
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients with standard indications for CRT based upon the most recent ESC/EHRA guidelines AND meeting criteria for one of these two categories:

  1. Patients with previously implanted pacemakers or ICD's and meeting standard indications for CRT but in whom standard CRT is not advisable due to known high risk - referred to as "upgrades". Justifications for not using standard CRT must be documented in a CRF.
  2. Patients in whom coronary sinus lead implantation or attempted implantation for CRT has failed to provide demonstrable therapy benefit - referred to as "untreated"

Exclusion criteria

Exclusion Criteria:

  1. Inability to comply with the study follow-up or other study requirements
  2. History of chronic alcohol/drug abuse and currently using alcohol/drugs
  3. Non-ambulatory (or unstable) class 4
  4. to heparin
  5. Contraindication to both chronic anticoagulants and antiplatelet agents
  6. Triple anticoagulation therapy (warfarin, clopidogrel, ASA, and other agents)
  7. Thrombocytopenia ( count \<150,000)
  8. Contraindication to iodinated contrast agents
  9. Intracardiac thrombus by transesophageal echocardiography
  10. Age less than 18 years or greater than 75
  11. Attempted IPG implant within 3 days
  12. of less than 12 months
  13. Chronic hemodialysis
  14. Stage 4 or 5 renal dysfunction defined as \<30
  15. Grade 4 mitral valve regurgitation
  16. Myocardial infarction within one month
  17. Major cardiac surgery within one month
  18. History of a pericardial effusion in prior procedures
  19. Female of , pregnant, or breastfeeding (a pregnancy test will be obtained where applicable)
  20. Non-cardiac implanted electrical stimulation therapy devices
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Implant

    Implant of the WiCS-LV system

    Device: WiCS-LV system

Interventions

  • DeviceWiCS-LV system

    Wireless cardiac stimulator implant to pace the left ventricle for CRT Transvascular endocardial implantation of wireless pacing Electrode and subcutaneous implantation of Implantable Pulse Generator

    Also known as: Implant

06

What researchers measure

Primary outcomes

  1. Number of patients with device-related adverse events as a measure of safety

    Device-related adverse events are those in which the WiCS-LV system is directly or indirectly responsible.

    Time frame: 24 hour peri-operative and one month

  2. Number of patients with procedure-related adverse events as a measure of safety

    Procedure-related adverse events are those which occur during the WiCS-LV system implant procedure.

    Time frame: 24 hour perioperative and one month

  3. Bi-ventricular pacing capture

    Bi-ventricular pacing capture documented on 12-lead EKG

    Time frame: one month

Secondary outcomes

  1. Number of patients with device-related adverse events as a measure of safety

    Device-related adverse events are those in which the WiCS-LV system is directly or indirectly responsible.

    Time frame: 6 months

  2. Number of patients with serious adverse events as a measure of safety

    Time frame: 6 months

  3. Bi-ventricular pacing capture

    Bi-ventricular pacing capture documented on 12-lead EKG

    Time frame: 6 months

  4. Clinical composite score

    Composite of all cause mortality, heart failure hospitalization, NYHA class, and patient global assessment

    Time frame: 6 months

  5. Change in echocardiographic indices

    change in left-ventricular end-systolic volume, left ventricular end-diastolic volume, and ejection fraction

    Time frame: 6 months

07

Study locations

2 sites
  • Na Homolce Hospital
    Prague, 150 30, Czechia
  • Aalborg University Hospital
    Aalborg, 9100, Denmark
08

References and documents

Publications

  • Reddy VY, Miller MA, Neuzil P, Sogaard P, Butter C, Seifert M, Delnoy PP, van Erven L, Schalji M, Boersma LVA, Riahi S. Cardiac Resynchronization Therapy With Wireless Left Ventricular Endocardial Pacing: The SELECT-LV Study. J Am Coll Cardiol. 2017 May 2;69(17):2119-2129. doi: 10.1016/j.jacc.2017.02.059. PubMed 28449772 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2013, a primary completion of Aug 2015 and a completion of Nov 2019. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2013
First posted
Jul 23, 2013
Start
Jul 2013
Primary completionActual
Aug 2015
CompletionActual
Nov 2019
Last update
Jul 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01905670
Lead sponsor
EBR Systems, Inc.
Responsible party
Sponsor
First posted
Jul 23, 2013
Start date
Jul 2013
Primary completion
Aug 2015
Completion
Nov 2019
Last update
Jul 9, 2020

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion